E7P Stock Chart & Stats
€30.20
--
Market closed
€30.20
--
Day’s Range― - ―
52-Week Range€19.80 - €36.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)5.00
Market Cap
€3.41B
Enterprise Value€5.37B
Total Cash (Recent Filing)€222.00M
Total Debt (Recent Filing)€509.00M
Price to Earnings (P/E)11.4
Beta0.02
Next Earnings
Oct 29, 2026EPS Estimate
0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.84
Shares Outstanding118,031,940
10 Day Avg. Volume1
30 Day Avg. Volume5
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-45.77
Price to Sales (P/S)3.62
P/FCF Ratio-47.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€40.60Price Target Upside34.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)3.76
Revenue Forecast (FY)€1.19B
Bulls Say, Bears Say
Bulls Say
SUBLOCADE Growth And ProtectionSUBLOCADE combines strong recent growth with substantial intellectual-property protection, supporting durable revenue potential. Its leading market position, record new patient starts, and long patent coverage provide a foundation for continued adoption and help protect the product from near-term generic erosion.
Merger Scale And SynergiesThe proposed combination would materially expand scale, diversify the commercial platform, and provide identified cost savings within 12 months of closing. A larger portfolio and stronger operating base could improve efficiency, support investment in growth products, and increase long-term cash-generation potential.
Profitability ReboundRecent operating results show accelerating revenue and product growth alongside substantially improved profitability. This rebound indicates better operating leverage and commercial execution, giving Indivior greater capacity to fund product development, support market expansion, and strengthen earnings over the coming quarters.
Bears Say
SUBLOCADE ConcentrationDependence on one major product leaves the combined business exposed to slower adoption, competitive changes, or market shifts affecting SUBLOCADE. Concentration can make revenue performance less resilient and places greater importance on sustaining market share while successfully scaling the rest of the portfolio.
Weak Cash Conversion And Negative EquityNegative operating and free cash flow despite positive TTM net income raises concerns about earnings quality and the company’s ability to self-fund operations and investment. Combined with persistently negative equity, this reduces financial resilience and could limit flexibility if cash conversion remains volatile.
Merger Execution And Added LeverageThe merger introduces approval, integration, and synergy-realization requirements that could delay benefits or raise execution costs. It also increases absolute indebtedness, meaning management must integrate two organizations while preserving commercial momentum and maintaining sufficient flexibility for future investment.
Indivior News
E7P FAQ
What was Indivior PLC’s price range in the past 12 months?
Indivior PLC lowest stock price was €19.80 and its highest was €36.20 in the past 12 months.
What is Indivior PLC’s market cap?
Indivior PLC’s market cap is €3.41B.
When is Indivior PLC’s upcoming earnings report date?
Indivior PLC’s upcoming earnings report date is Oct 29, 2026 which is in 10 days.
How were Indivior PLC’s earnings last quarter?
Indivior PLC released its earnings results on Aug 03, 2026. The company reported €0.997 earnings per share for the quarter, beating the consensus estimate of €0.753 by €0.244.
Is Indivior PLC overvalued?
According to Wall Street analysts Indivior PLC’s price is currently Undervalued.
Does Indivior PLC pay dividends?
Indivior PLC does not currently pay dividends.
What is Indivior PLC’s EPS estimate?
Indivior PLC’s EPS estimate is 0.92.
How many shares outstanding does Indivior PLC have?
Indivior PLC has 118,031,940 shares outstanding.
What happened to Indivior PLC’s price movement after its last earnings report?
Indivior PLC reported an EPS of €0.997 in its last earnings report, beating expectations of €0.753. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Indivior PLC?
Currently, no hedge funds are holding shares in DE:E7P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Indivior Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€40.60 (34.44% Upside)
€40.60 (34.44% Upside)
Blogger Sentiment
Bullish
DE:E7P Sentiment 86%
Sector Average 67%
Sector Average 67%
Insider Transactions
Bought Shares
Worth €96.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
31.42%
12-Months-Change
Fundamentals
Return on Equity
-216.13%
Trailing 12-Months
Asset Growth
-15.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Indivior PLC
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
E7P Company Deck
E7P Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call presents a constructive and optimistic view of the merger: management emphasized scale, a diversified portfolio (~$2.2B pro forma revenue), strong pro forma profitability (adjusted EBITDA $888M; ~41% margin), and $125M of near-term cost synergies, while retaining balance sheet strength and highlighting SUBLOCADE as a durable, large growth driver (~44% of revenue) supported by IP and commercial momentum. Noted risks include revenue concentration in SUBLOCADE, increased pro forma net debt (~$878M, ~1x leverage), absence of quantified revenue synergies, and standard integration and regulatory execution risks. On balance, the positives (scale, margins, synergies, product durability) outweigh the lowlights.View all DE:E7P earnings summariesE7P Stock 12 Month Forecast
Average Price Target
€40.60
▲(34.44% Upside)
Technical Analysis
Neurocrine
―
Supernus Pharmaceuticals
―
Teva
―
Collegium Pharmaceutical
―
Amneal Pharmaceuticals
―